Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PreArthos is a multi-ingredient dietary supplement developed by PreEmptive Meds (PMeds) as part of their "pre-disease" product line. It is specifically formulated to support joint health and address early-stage joint degradation, which the company refers to as "pre-arthritis." The supplement contains a blend of structural components for cartilage, such as glucosamine sulfate and chondroitin sulfate, alongside methylsulfonylmethane (MSM) and several botanical extracts with anti-inflammatory properties, including Boswellia serrata, turmeric (curcumin), ginger, quercetin, and bromelain. PreArthos is intended to maintain joint mobility and reduce systemic inflammation associated with joint wear and tear before the progression to clinical osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PreArthos.